Researchers conducted a Phase 2 clinical trial to learn about a drug called DS-1062a. They studied it in 137 people with advanced or metastatic non-small cell lung cancer (NSCLC) who had specific genetic changes in their cancer. All participants had already received at least one platinum-based chemotherapy and one or more targeted therapies for their cancer. The main goal was to see how well the drug worked, how safe it was, and how it was processed by the body.
The trial was designed to measure the percentage of participants whose tumors shrank significantly, which is called the objective response rate. This measurement was planned to be reviewed by an independent central team to avoid bias. The study did not compare DS-1062a to another treatment or a placebo.
No results from this specific trial are available in the provided information. This means we do not yet know if the drug was effective, how patients tolerated it, or what side effects occurred. The trial was sponsored by the drug's developer, Daiichi Sankyo.
It is important to remember that this was a Phase 2 trial, which is a mid-stage study designed to gather initial evidence about a drug's effectiveness and safety. These studies are not large enough to provide definitive proof. Readers should understand that this report only describes a study that was conducted, not its outcomes. The findings, when they become available, will need to be confirmed in larger Phase 3 trials before the drug could be considered for approval.
